Tag:
OXiGENE
Latest Headlines
Latest Headlines
Cash-strapped Oxigene lays off staffers, shelves PhIII study
The once high-flying Oxigene says it doesn't have the cash to fund a late-stage study of its cancer drug Zybrestat and will pink-slip 11 workers--more than half its remaining staff--as the biotech
"ASCO effect" drives up shares of troubled OXiGENE
Call it ASCO fever. Investors tend to get extra excited about cancer drug developer stocks around the time of the annual American Society of Clinical Oncology meeting in June. This year's top
OXiGENE filing includes going concern opinion
South San Francisco-based OXiGENE says auditors have expressed doubts about the company's ability to continue as a going concern. "We will be required to raise additional funds to finance our
OXiGENE axes half its staff, halts enrollment in restructuring
OXiGENE is restructuring, cutting its 41-person workforce by 20 and halting further enrollment for a Phase II/III trial on thyroid cancer. The developer says that it will concentrate its efforts on a
OXiGENE swaps shares for VaxGen and $33M in cash
OXiGENE plans to fork over $22 million worth of its shares to acquire VaxGen, gaining the developer's programs and $33 million in cash to fund its operations. VaxGen shareholders will get 0.4719 of a
Oxigene gets $40M for pipeline work
Symphony Capital Partners is handing over $40 million to Oxigene to help the company advance its pipeline of vascular disrupting agent drug candidates for cancer and eye disease. Symphony will
ALSO NOTED: Ardana looks to sale or merger; Oxigene inks $40M capital deal; and much more...
> Edinburgh-based Ardana's CEO, says the biotech is looking for a sale or merger. Report > Oxigene has
ALSO NOTED: FDA to speed up generic approval; Genfit starts Phase II trials; and much more...
Could the steady trickle of generics approvals out of the FDA suddenly become a rapid stream? The agency is touting an initiative, called Generic Initiative for Value and Efficiency (GIVE), to speed
